| Citation: |
DONG Shuang, WANG Jun, HU Sheng, LIAO Guoxiang, RAN Fengming. Aprepitant versus Olanzapine for Prevention of Nausea and Vomiting Induced by Multi-day Chemotherapy in Female Lung Cancer or Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 356-359. DOI: 10.3971/j.issn.1000-8578.2017.05.009
|
To compare the effectiveness, safety and cost-effectiveness ratio between Olanzapine (OLN) and Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in female patients who received multi-day cisplatin-based chemotherapy.
Eighty-seven female patients were randomized to receive Aprepitant (44 cases) or Olanzapine (43 cases). Antiemetic regimen received by Aprepitant group and olzanpine group were as follows. Aprepitant group: Aprepitant, Tropisetron and Dexamethasone; Olanzapine group: Olanzapine, Tropisetron and Dexamethasone.
No substantial difference was found in complete response rate of delayed emesis in Aprepitant group (29/44) and in Olanzapine group (30/43), (65.9% vs. 69.8%, P=0.690). Higher hiccup incidence was found in Aprepitant group (31.8%, P=0.023) while a more pronounced drowsiness effect was observed in Olanzapine group (25.6%, P=0.006). Hematological toxicity between the two groups was of no significant difference. Yet, the cost of Aprepitant group per cycle was much higher than that of Olanzapine group (P < 0.01).
In female lung and breast cancer patients, the safety and effectiveness of Aprepitant combined with Dexamethasone and Tropisetron are similar to those of Olanzapine regarding delayed nausea and vomiting induced by 3 days Cisplatin chemotherapy, but the latter is more cost-effective.
| [1] |
Yuan DM, Li Q, Zhang Q, et al.Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials[J].Asian Pac J Cancer Prev, 2016, 17(4): 1661-75. doi: 10.7314/APJCP.2016.17.4.1661
|
| [2] |
董爽, 于世英.肿瘤化疗所致恶心呕吐现状调查[J].中国循证医学杂志, 2013, 13(6): 687-91. doi: 10.7507/1672-2531.20130122
Dong S, Yu SY.Status survey on chemotherapy-induced nausea and vomiting[J].Zhongguo Xun Zheng Yi Xue Za Zhi, 2013, 13(6): 687-91. doi: 10.7507/1672-2531.20130122
|
| [3] |
Navari RM, Aapro M.Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting[J].N Engl J Med, 2016, 374(14): 1356-67. doi: 10.1056/NEJMra1515442
|
| [4] |
Grunberg SM, Dugan M, Muss H, et al.Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy[J].Support Care Cancer, 2009, 17(5): 589-94. doi: 10.1007/s00520-008-0535-9
|
| [5] |
Multinational Association of Supportive Care in Cancer.A Mascc/Esmo Antiemetic Guideline Version 1.2 2016[EB/OL].[2016-03-26].http://www.mascc.org/assets/Guidelines-Tools/masccantiemetic guidelines English 2016 v.1.2.pdf.
|
| [6] |
NCCN.Clinical Practice Guidelines in Oncology: antiemesis Version 2.2016 [EB/OL].[2016-04-15].https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
|
| [7] |
DeRemer DL, Clemmons AB, Orr J, et al.Emerging role of olanzapine for prevention and treatmentof chemotherapy-induced nauseaand vomiting[J].Pharmacotherapy, 2016, 36(2): 218-29. doi: 10.1002/phar.2016.36.issue-2
|
| [8] |
Navari RM, Nagy CK, Gray SE.The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy[J].Support Care Cancer, 2013, 21(6): 1655-63. doi: 10.1007/s00520-012-1710-6
|
| [9] |
Roscoe JA, Heckler CE, Morrow GR, et al.Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy[J].J Clin Oncol, 2012, 30(27): 3389-95. doi: 10.1200/JCO.2011.39.8123
|
| [10] |
Hesketh PJ.Chemotherapy-induced nausea and vomiting[J].N Engl J Med, 2008, 358(23): 2482-94. doi: 10.1056/NEJMra0706547
|
| [11] |
Fernández-Ortega P, Caloto MT, Chirveches E, et al.Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life[J].Support Care Cancer, 2012, 20(12): 3141-8. doi: 10.1007/s00520-012-1448-1
|
| [12] |
Gao HF, Liang Y, Zhou NN, et al.Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy[J].Intern Med J, 2013, 43(1): 73-6. doi: 10.1111/j.1445-5994.2011.02637.x
|
| [13] |
Olver IN, Grimison P, Chatfield M, et al.Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy[J].Support Care Cancer, 2013, 21(6): 1561-8. doi: 10.1007/s00520-012-1696-0
|
| [14] |
Gralla RJ.Palliative care: Aprepitant and control of emesis induced by 5-day chemotherapy[J].Nat Rev Clin Oncol, 2012, 9(11): 614-6. doi: 10.1038/nrclinonc.2012.183
|
| [15] |
Albany C, Brames MJ, Fausel C, et al.Randomized, double-blind, placebo-controlled, phase iii cross-over study evaluating the oral neurokinin-1 antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study[J].J Clin Oncol, 2012, 30(32): 3998-4003. doi: 10.1200/JCO.2011.39.5558
|
| [16] |
Navari RM, Gray SE, Kerr AC.Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase Ⅲ trial[J].J Support Oncol, 2011, 9(5): 188-95. doi: 10.1016/j.suponc.2011.05.002
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: